A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic...

Area of Science:

• Immunogenetics
• Rheumatology
• Pulmonary Medicine

Background:

• Systemic sclerosis (SSc) is an autoimmune disease with complex genetic underpinnings.
• The Major Histocompatibility Complex (MHC) and complement component 4 (C4) are implicated in autoimmune diseases.
• Understanding genetic contributions to SSc, pulmonary fibrosis, and autoantibody expression is crucial for disease management.

Purpose of the Study:

• To investigate the role of MHC and C4 alleles in systemic sclerosis (SSc).
• To determine the association of these genetic factors with pulmonary fibrosis and autoantibody expression in SSc patients.
• To analyze genetic markers at the DNA level for disease susceptibility and clinical manifestations.

Main Methods:

• DNA analysis of MHC class I and class II alleles (DRB, DQA, DPB) using RFLP and PCR.
• C4 gene analysis via protein phenotyping and RFLP.
• Correlation analysis between genetic markers, SSc status, pulmonary fibrosis, and autoantibodies (ACA, anti-Scl-70).

Main Results:

• The C4A-null phenotype was the strongest disease association factor (P=0.000064, RR=2.8).
• DQA2 was identified as the primary MHC susceptibility allele (Pcorr=0.0009, RR=2.5), linked with DR3 and DR11.
• DR2 showed a protective effect in female patients (P=0.0021, RR=0.42).
• DR52a was associated with pulmonary fibrosis.
• Anticentromere antibodies (ACA) linked to DR1/DR4 (P=0.0015, RR=6.7).
• Anti-Scl-70 correlated with DPB1:69:E (P=0.0063, RR=4.6).

Conclusions:

• The C4A locus is the most significant genetic marker for SSc susceptibility.
• C4AQ0 and DQA2 are independent SSc susceptibility factors.
• Combined MHC and autoantibody analysis can predict pulmonary fibrosis development in SSc.
• MHC alleles linked to autoantibodies are not direct markers for SSc susceptibility.